Atea Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 4.31 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 345.68M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of ...